Unaudited Interim Results to 30 June 2025
RNS Announcements
Share Subscription and Proposed Board Appointment
04 September 2024
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to
support cardiometabolic health, announces that is has raised £1,226,400 through a
share subscription with the Company (the “Subscription”). Following completion of
the Subscription, the Company expects to be fully funded enabling it to fulfil all
its working capital requirements with no recourse for further funding.
Subscription
ProBiotix is pleased to announce that Holdingselskabet af 29. Juni 2010 Aps, the
family office vehicle of successful Denmark based investor and entrepreneur,
Frederik Bruhn-Petersen, has subscribed for 36,500,000 new ordinary shares of 0.05p
each in the Company (“Ordinary Shares”, “New Ordinary Shares”) at a subscription
price of 3.36p per share, raising £1,226,400 (before expenses).
The net proceeds of the Subscription will be used to fund working capital and help
the Company further its expansion by accelerating a number of significant growth
opportunities.
The New Ordinary Shares will represent approximately 23% of the Company's issued
share capital following the Subscription and will rank pari passu in all respects
with the existing Ordinary Shares. Application will be made for the New Ordinary
Shares to be admitted to trading on the Access Segment of the Aquis Growth Market
and dealings in the New Ordinary Shares are expected to commence on 10 September
2024 (“Admission”).
Proposed Board Appointment
Following the Subscription, the Company plans to appoint Frederik Bruhn-Petersen, the
identically named son of Frederik Bruhn-Petersen, to the Board of Directors of
ProBiotix as a Non-Executive Director (subject to completion of satisfactory due
diligence). Frederik Bruhn-Petersen, who is currently working in a managing role for
Holdingselskabet af 29. Juni 2010 Aps, has a Masters of Law Degree from Copenhagen
University and is the co-founder of one of Denmark's most successful real estate
companies, driving the business from a start-up phase to a national online
operator.
Total Voting Rights
Following Admission, the Company's enlarged share capital will comprise 158,166,666
Ordinary Shares. The figure of 158,166,666 Ordinary Shares may be used by
shareholders in the Company as the denominator for the calculation by which they may
determine if they are required to notify their interest in, or a change in their
overall interest in, the share capital of the Company under the Financial Conduct
Authority's Disclosure and Transparency Rules.
Steen Andersen, CEO of ProBiotix, commented: "On behalf of the
Board, I would like to thank Frederik for his support and welcome him (and his
family office) as a significant new shareholder in ProBiotix, and also welcome
his son Frederik as a proposed new Non-Executive Director. I have known both
individuals for many years.
“With the business now on a strong financial footing, I look forward to working
with Frederik, his son and the rest of the Board as we continue to accelerate
the growth of the business.”
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
ProBiotix Health plc | https://probiotixhealth-ir.com/ |
Steen Andersen, Chief Executive Officer | Contact via Walbrook below |
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) | Tel: 020 7220 9793 |
Mark Anwyl Duncan Vasey |
Tel: 020 7469 0930 |
Walbrook PR Ltd | probiotix@walbrookpr.com |
Anna Dunphy | Mob: 07876 741 001 |
Aquis-listed ProBiotix Health
taps into demand for
cardiovascular disease treatments
Stephen O'Hara | 23
February 2023
IG UK | Youtube